RxDoctor Payments Data

Veesha Tomashevsky, MD

Child & Adolescent Psychiatry · New York, NYNPI 1477565877

Payments from drug & device makers

$966in general payments, 2019–2025

Across 78 payments — averaging $12.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$749
  • Lundbeck LLC$83
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$34
  • Viiv Healthcare Company$34
  • Vanda Pharmaceuticals Inc.$29
  • Takeda Pharmaceuticals U.S.A., Inc.$22
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$966100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$966 in reported general payments places this provider in the 75th percentile of 317 child & adolescent psychiatry providers in New York.

See all child & adolescent psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$31,838
Medicare patients
35
Services billed
396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole95$133,658
CaplytaLumateperone Tosylate24$41,770
VraylarCariprazine Hcl24$32,528
TrintellixVortioxetine Hydrobromide45$21,650
FetzimaLevomilnacipran Hcl14$6,791
Aripiprazole101$3,195
Divalproex Sodium ErDivalproex Sodium46$2,001
Pregabalin46$1,904
Duloxetine Hcl160$1,385
Olanzapine51$1,230
Naltrexone Hcl37$1,191
Quetiapine Fumarate93$1,188
Oxcarbazepine53$1,127
Gabapentin94$1,121
Mirtazapine161$978

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$16$133,65895 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$34$41,77024 claims
AbbVieVraylar, Fetzima$749$39,32038 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$22$21,65045 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 317 child & adolescent psychiatry providers in New York.

Other child & adolescent psychiatry in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →